Biosafety
Does This Study Require IBC Review?
While clinical research professionals are familiar with the role of the IRB to protect research subjects, most are unfamiliar with the added need for an Institutional Biosafety Committee (IBC).
Reflections from Cell and Gene Meeting on the Mesa 2021
This blog recounts the 2021 Cell and Gene Meeting on the Mesa conference, including details on cell and gene therapy's growth and trajectory.
A Changing World in Gene Therapy Research: Exciting Opportunities for Medical Advancement and Biosafety Challenges
Our IBC experts authored the article “A Changing World in Gene Therapy Research: Exciting Opportunities for Medical Advancement and Biosafety...
Why Institutions Should Consider an Externally Administered IBC
Gene therapy clinical trials require specialized oversight & expertise. Read how institutions can prep for the boom in gene therapy research.
Understanding the Current and Future States of Cell and Gene Therapy Research
This white paper focuses on gene therapy uses in oncology and looks at a successful program at an NCI-designated comprehensive cancer center.
Advarra Announces Key Growth Milestone for The Gene Therapy Ready Network, Becoming Largest IBC Service
Advarra's network has grown to over 500 registered research sites, becomes the largest administrator of institutional biosafety committees
Cell & Gene Therapy vs Drug Research: What’s the Difference?
In the past year, cell and gene therapy research has exploded. Understand how this field differs from traditional drug development.
IBC Overview eLearning Module
Institutional biosafety committee oversight is necessary to ensure the safety of those involved in research with engineered genetic materials.
Daniel Eisenman, Paul Gulig, and Adam Soloff Explore The Exponential Rise of Gene Therapy and Unlocking Its Potential Promise
In this podcast, Daniel Eisenmann talks with Adam Soloff and Paul Gulig for a discussion on the growth and the promise of gene therapy.
Pitfalls of Chemistry, Manufacturing, and Controls in Investigational New Drug Preparation
Submitting an Investigational New Drug (IND) application for the first time? Consider three common CMC pitfalls that may impact submission.
World’s Largest CRO Leverages Partnership With Integrated Central IBC to Initiate Sites in COVID-19 Vaccine Research at Warp Speed
Advarra’s IRB and IBC reviews and Gene Therapy Ready site network helped reduce study startup timelines and delivered trial results to the sponsor quicker than expected.
Subscribe to our monthly email
Receive updates monthly about webinars for CEUs, white papers, podcasts, and more.
Advancing Clinical Research: Safer, Smarter, Faster™
Copyright © 2024 Advarra. All Rights Reserved.